GLP1R and metabolic dysfunction-associated steatotic liver disease: Through preclinical and clinical studies, researchers determined that postprandial levels of GLP-1 were decreased in MASLD and MASH patients (8.8 ± 0.7 pmol/L in patients vs. 11.7 ± 1.0 pmol/L in healthy controls; p < 0.001), while GLP-1RA treatment in mice was able to reduce hepatic steatosis [42–44].